Skip to main
INCY
INCY logo

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 35 analyst ratings
Buy
Strong Buy 34%
Buy 20%
Hold 40%
Sell 6%
Strong Sell 0%

Bulls say

Incyte's positive outlook is supported by robust fourth-quarter performance driven by strong demand for Jakafi, which generated $773 million in revenue, surpassing expectations and indicating limited competition impact. The success of their first dermatology product, Opzelura, is underscored by significant patient improvement metrics, showcasing its potential in the atopic dermatitis market. Additionally, Incyte's strategically positioned pipeline, including promising assets like povorcitinib, is expected to sustain revenue growth amid the anticipated Jakafi patent expiration in 2028, reinforcing a stable foundation for long-term performance.

Bears say

Incyte faces significant challenges that contribute to a negative outlook on its stock, primarily due to eroding pricing power for its leading drug, Jakafi, and potential competition in the market. The firm's pipeline is under scrutiny as there are concerns regarding the efficacy of earlier-stage products and the risks associated with clinical and regulatory setbacks, which may hinder future growth. Additionally, management's acknowledgment of uncertainties in upcoming clinical trials raises concerns about the company's ability to meet sales expectations, further compounding the pressures on Jakafi’s market position and overall financial performance.

Incyte (INCY) has been analyzed by 35 analysts, with a consensus rating of Buy. 34% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 35 analysts, Incyte (INCY) has a Buy consensus rating as of Jul 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.